Pathology & Oncology Research

, Volume 20, Issue 4, pp 819–828 | Cite as

Utility of Immunohistochemical Markers in Diagnosis of Follicular Cell Derived Thyroid Lesions

Research

Abstract

Differentiating the follicular derived lesions can be challenging. Although immunohistochemistry is generally accepted as a useful ancillary technique in the diagnosis, controversy exists regarding the best marker or combination of markers to distinguish each lesion from its mimics. In this study, we aimed at evaluating multiple markers to compare their sensitivity and usefulness, and to find out if a combination of the evaluated markers can be of additional value in discriminating thyroid lesions. The study included two groups of follicular derived thyroid lesions; benign group (Grave’s disease, nodular goiter, Hashimoto’s and adenoma) and malignant group (papillary, follicular carcinoma, well differentiated tumors of unknown malignant potential and follicular tumour of unknown malignant potential). Immunohistochemical evaluation of CD56, HBME-1, Gaectin-3 and CK19 were done. The sensitivity, specificity for each marker and their combination were calculated. Each marker was sensitive and specific for certain lesion but the sensitivity and specificity was increased when use combination of markers. Although no single marker is completely sensitive and specific for follicular thyroid lesions, the combination of CD56, HBME-1, Gaectin-3 and CK19 attains high sensitivity and specificity in diagnosis.

Keywords

Thyroid carcinoma Immunohistochemistry CD56 HBME-1 Gatectin-3 CK19 

References

  1. 1.
    Ying YL, Hans M, Job K et al (2008) Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-g, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol 158:375–384CrossRefGoogle Scholar
  2. 2.
    Guido F, Esther DR, Marco R et al (2011) Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol 165:447–453CrossRefGoogle Scholar
  3. 3.
    Yoon LC, Mi KK, Jin-Won S et al (2005) Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci 20(5):853–859CrossRefGoogle Scholar
  4. 4.
    Yasuhiro I, Hiroshi Y, Chisato T et al (2005) HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res 25:179–182Google Scholar
  5. 5.
    Arturs O, Zenons N, Ilze S et al (2012) Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina (Kaunas) 48(10):507–514Google Scholar
  6. 6.
    Mauro P, Jaime R, Roberta DP et al (2005) Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541–546CrossRefGoogle Scholar
  7. 7.
    Dina ED, Ahmed N, Salem A (2008) Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 3–5Google Scholar
  8. 8.
    Jeffrey L, Bhuvanesh S, Giovanni T et al (2006) Follicular variant of papillary thyroid carcinoma. A clinicopathologic study of a problematic entity. Cancer 107(6):1255–1264CrossRefGoogle Scholar
  9. 9.
    Debdas B, Ram ND, Uttara C et al (2012) Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Indian J Med Paediatr Oncol 33(2):107–111CrossRefGoogle Scholar
  10. 10.
    Rasha MA, Lobna SS (2012) Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Cancer Inst 24:175–184CrossRefGoogle Scholar
  11. 11.
    Husain AS, Jining F, Farah T et al (2009) Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal 6:18PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Young JP, Soo HK, Dong CK et al (2007) Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27kip1 in the differential diagnosis of thyroid nodules. J Korean Med Sci 22(4):621–628CrossRefGoogle Scholar
  13. 13.
    Sandrine R, Brahim E, Sergio F et al (2002) Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol 15(12):1294–1301CrossRefGoogle Scholar
  14. 14.
    Prasad ML, Pellegata NS, Huang Y et al (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48–57PubMedCrossRefGoogle Scholar
  15. 15.
    de Matos PS, Ferreira AP, de Oliveira FF et al (2005) Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47:391–401PubMedCrossRefGoogle Scholar
  16. 16.
    Ozolins A, Narbuts Z, Strumfa I et al (2010) Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg 395(7):885–891PubMedCrossRefGoogle Scholar
  17. 17.
    DeLellis RA (2006) Pathology and genetics of thyroid carcinoma. J Surg Oncol 94(8):662–669PubMedCrossRefGoogle Scholar
  18. 18.
    Chan JK (2002) Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 117:16–18PubMedCrossRefGoogle Scholar
  19. 19.
    Williams ED (2000) Two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 8:181–183PubMedCrossRefGoogle Scholar
  20. 20.
    Park WY, Jeong SM, Lee JH et al (2009) Diagnostic value of decreased expression of CD56 protein in papillary carcinoma of the thyroid gland. Basic Appl Pathol 2:63–68CrossRefGoogle Scholar
  21. 21.
    Nasr MR, Mukhopadhyay S, Zhang S et al (2006) Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME 1 combined with CK-19 immunostaining. Mod Pathol 19:1631–1637PubMedCrossRefGoogle Scholar
  22. 22.
    Husain AS, Bo J, John B et al (2010) Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 5:9CrossRefGoogle Scholar
  23. 23.
    Qingbin S, Deguang W, Yi L et al (2011) Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol 6:126–131CrossRefGoogle Scholar
  24. 24.
    Shin MK, Kim JW, Ju Y (2011) CD56 and high molecular weight keratin as dignostic markers of papillary thyroid carcinoma. Korean J Pathol 45:477–484CrossRefGoogle Scholar
  25. 25.
    Etem H, Ozekinci S, Mizrak B et al (2010) The role of CD56, HBME-1, and p63 in follicular neoplasms of the thyroid. J Pathol 26:238–242Google Scholar
  26. 26.
    Miettinen M, Karkkainen P (1996) Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Virchows Arch 429:213–219PubMedGoogle Scholar
  27. 27.
    Cheung CC, Ezzat S, Freeman JL et al (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338–342PubMedCrossRefGoogle Scholar
  28. 28.
    Gasbarri A, Martegani MP, Del Prete F et al (1999) Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 17:3494–3499PubMedGoogle Scholar
  29. 29.
    Saggiorato E, De Pompa R, Volante M et al (2005) Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocrinol Relat Cancer 12:305–317CrossRefGoogle Scholar
  30. 30.
    Orlandi F, Saggiorato E, Pivano G et al (1998) Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58:3015–3020PubMedGoogle Scholar
  31. 31.
    Kovacs RB, Foldes J, Winkler G et al (2003) The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol 149(5):449–453PubMedCrossRefGoogle Scholar
  32. 32.
    Bartolazzi A, Gasbarri A, Papotti M et al (2001) Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644–1650PubMedCrossRefGoogle Scholar
  33. 33.
    Collet JF, Fajac A (2006) Galectin-3 immunodetection in thyroid fine-needle aspirates: technical procedure and results. Ann Pathol 26:347–351PubMedCrossRefGoogle Scholar
  34. 34.
    Kim MJ, Kim HJ, Hong SJ et al (2006) Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol 50:28–34PubMedCrossRefGoogle Scholar
  35. 35.
    Sahoo S, Hoda SA, Rosai J et al (2001) Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma. Am J Clin Pathol 116:696–702PubMedCrossRefGoogle Scholar
  36. 36.
    Guyetant S, Michalak S, Valo I et al (2003) Diagnosis of the follicular variant of papillary thyroid carcinoma significance of immunohistochemistry. Ann Pathol 23:11–20PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2014

Authors and Affiliations

  1. 1.Department of Pathology, Faculty of MedicineTanta UniversityTantaEgypt

Personalised recommendations